Prometheus Biosciences Inc.

Prometheus Biosciences Inc.

World Rank (Aug-2026)
1740
World Rank (Jan-05-2024)
1,740
World Rank (Jul-30-2023)
1,740
Market Cap (Jul-30-2023)
9.560 Billion USD
World Rank (Jan-07-2022)
7,819
Market Cap (Jan-07-2022)
1.381 Billion USD
World Rank (Jan-01-2021)
8,422
Company Rank in Country in 2023
Rank in USA in July-2023 is 646
Headquarters Country
USA
Employee Count
97
Employee Count as of Date
As on 2022
Headquarters City/State
California
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
7 Million USD
Annual Operating Income in USD
-146 Million USD
Annual Net Income in USD
-142 Million USD
Annual Results for Period Ending
For year ending December-2022
Total Assets in USD
741 Million USD
Total Liabilities in USD
65 Million USD
Total Equity in USD
676 Million USD
Balance Sheet for Period Ending
As of December-2022
Business Sector
Healthcare
Biotechnology
Company Website
PROMETHEUS BIOSCIENCES, INC.
Yahoo
Yahoo @ Nasdaq
Company Profile

Prometheus Biosciences, Inc. is a biotechnology company focused on the precision approach is designed to transform the treatment of immune-mediated diseases starting with inflammatory bowel disease (IBD). The company annual revenue is 3 million USD and annual net loss of 90 million USD for year ending December 2021. The headquarters is in USA.

Merck acquired Prometheus Biosciences Inc. for 11 billion USD in the year 2022.

IPO Year
2021

Share